The most common subtype of renal cell carcinoma (RCC), clear cell RCC (ccRCC), occurs in more than three quarters of RCC patients. Nearly a third of those patients present with metastasis at the time of diagnosis, and another third develop either local recurrence or distant metastases even after the initial treatment. The five-year survival rate of patients with advancestage ccRCC remains at a devastatingly low 10%. A distinguishing characteristic of ccRCC is a highly vascularized tumor microenvironment due to upregulation of pro-angiogenic factor VEGF. While targeting VEGF and other pro-angiogenic signaling pathways tends to yield positive results initially, virtually all patients eventually develop resistance to current treatments.
Gau, D., Chawla, P., Xu, K., Welling, N., Antonello, J., Consoli, C., Wei, M., Zdancewicz, S., DaSilva, M., Varghese, C., Francoeur, P., Shi, H., Chen, X., Paranjape, A., Villanueva, F., Smithgall, T. E., VanDemark, A., Koes, D. R., Huryn, D. M., & Roy, P. (2026). Small molecule intervention of actin-binding protein profilin1 reduces tumor angiogenesis in renal cell carcinoma. Journal of Biological Chemistry, 302(2), Article 111033. https://doi.org/10.1016/j.jbc.2025.111033
Allen, A., Gau, D., Francoeur, P., Sturm, J., Wang, Y., Martin, R., Maranchie, J., Duensing, A., Kaczorowski, A., Duensing, S., Wu, L., Lotze, M. T., Koes, D., Storkus, W. J., & Roy, P. (2020). Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. Journal of Biological Chemistry, 295(46), 15636–15649. https://doi.org/10.1074/jbc.ra120.013963